Advertisement
EXEL vs INCY
Which Stock Would AI Choose? Exelixis (EXEL) vs. Incyte (INCY) Stock Comparison
Key Takeaways
- EXEL (Exelixis) is a profitable oncology company with accelerating momentum, while INCY (Incyte) is a larger, diversified biopharmaceutical firm navigating a recent quarterly loss and pipeline transition.
- Tickeron AI Verdict: EXEL — driven by stronger trend consistency, profitability, and clearer near-term catalysts relative to INCY.
- EXEL shares have risen roughly 51% year to date, well ahead of INCY's roughly 18% advance, reflecting divergent momentum.
- INCY posted a 14% revenue increase in its latest quarter but swung to an adjusted loss tied to an acquisition, while EXEL delivered both revenue and earnings growth.
- For more on each company, explore EXEL Major News and EXEL Today's Price Move, as well as INCY Major News and INCY Today's Price Move.
- To see how automated strategies are currently positioned across the market, browse the Trending AI Robots page.
Introduction
Exelixis (EXEL) and Incyte (INCY) are two oncology-focused biopharmaceutical companies at different stages of their commercial lifecycles. Exelixis is a concentrated, profitable business built around a single flagship franchise, while Incyte operates a broader portfolio spanning hematology, oncology, and dermatology. Comparing these two names offers a useful lens on contrasting risk profiles, growth drivers, and market positioning. Growth-oriented traders may favor Exelixis' momentum and earnings stability, while investors seeking diversification and a deeper pipeline may find Incyte's scale compelling. This stock comparison examines recent performance, sentiment shifts, and the relative positioning of both tickers.
EXEL Overview and Recent Performance
Exelixis (EXEL) is a biotechnology company focused on developing and commercializing cancer therapies. Its revenue engine is cabozantinib, sold as Cabometyx, which is approved for advanced renal cell carcinoma (RCC), previously treated hepatocellular carcinoma, and certain neuroendocrine tumors (NET). In recent weeks, the company reported quarterly revenue of roughly $659 million, up about 10% year over year, with adjusted earnings per share (EPS) of $0.94 that exceeded consensus estimates. Net product revenue growth was driven by higher volume and pricing for Cabometyx, whose prescription share in the oral tyrosine kinase inhibitor (TKI) market continued to climb.
Sentiment has been supported by steady franchise growth, disciplined capital allocation including an active share repurchase program, and a pipeline headlined by zanzalintinib, the company's next-generation therapy. That said, the regulatory review of zanzalintinib in colorectal cancer was extended, and management held full-year revenue guidance rather than raising it. Shares have outperformed the broader market in recent weeks, with a year-to-date gain of roughly 51%, reflecting strong relative momentum.
INCY Overview and Recent Performance
Incyte (INCY) is a global biopharmaceutical company with a diversified commercial portfolio. Its lead product, Jakafi (ruxolitinib), a JAK1/JAK2 inhibitor used for myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD), remains the largest single revenue contributor. The company also markets Opzelura cream for atopic dermatitis and vitiligo, as well as a growing hematology-oncology portfolio including Niktimvo, Zynyz, and Monjuvi/Minjuvi.
In recent market activity, Incyte reported quarterly revenue of about $1.56 billion, up 14% year over year, led by a 36% increase in Opzelura sales and strong growth across newer products. However, the company posted an adjusted net loss of $3.60 per share for the quarter, driven primarily by in-process research and development (IPR&D) expenses tied to its acquisition of Vega Therapeutics. Analysts have highlighted a credible path to growth beyond Jakafi, which faces loss of exclusivity near the end of the decade, while noting the company's expanding pipeline in myeloproliferative neoplasms and gastrointestinal oncology. Shares have risen roughly 18% year to date, a solid but more measured advance than EXEL.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of automated trading strategies from a broader universe of AI-driven bots that monitor and trade thousands of tickers. Because only the most suitable strategies for current market conditions earn a place in this curated section, the page serves as a practical starting point for traders evaluating data-driven approaches. The available robots span a wide range of trading styles, timeframes, performance metrics, and target-ticker sets, with many bots reporting their own historical statistics across different market regimes. Each bot operates on a distinct strategy and risk profile, so no single approach fits every investor. Readers interested in automated, rules-based market analysis are encouraged to review the Trending AI Robots page to explore current selections.
Head-to-Head Comparison
The two companies present a clear contrast in business model. Exelixis is highly concentrated, with the vast majority of revenue derived from a single molecule, cabozantinib. This focus produces strong margins and profitability but concentrates execution risk. Incyte, by contrast, is more diversified across products and indications, which reduces single-product risk but currently introduces earnings volatility, as evidenced by the recent quarterly loss tied to acquisition-related charges.
On growth drivers, Exelixis' near-term story hinges on Cabometyx volume growth and the eventual approval of zanzalintinib. Incyte's narrative rests on Opzelura momentum, newer hematology-oncology products, and a pipeline targeting high-incidence cancers. From a momentum standpoint, EXEL has demonstrated stronger relative performance, while INCY carries a larger market capitalization and broader revenue base. Risk factors also differ: Exelixis faces pipeline-timeline and concentration risk, whereas Incyte contends with the approaching loss of exclusivity on Jakafi and pipeline-dependent long-term growth. These trade-offs shape distinct market positioning for each ticker.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and relative positioning, Tickeron's AI would likely favor EXEL over INCY in the current environment. Exelixis combines profitability, a stronger recent price trend, and well-defined catalysts with disciplined capital returns, characteristics that typically align with favorable momentum signals. Incyte's broader diversification and deeper pipeline are meaningful long-term attributes, but its recent earnings volatility and heavier reliance on future pipeline execution introduce greater near-term uncertainty. This assessment is probabilistic and reflects current conditions rather than a definitive forecast of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and INCY is a Hold.
Momentum Indicator for EXEL turns positive, indicating new upward trend
EXEL saw its Momentum Indicator move above the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 66 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for EXEL just turned positive on October 09, 2026. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in 208 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 169 of 271 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for EXEL moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 24 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
EXEL broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.349) is normal, around the industry mean (2.788). P/E Ratio (21.146) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (6.305) is also within normal values, averaging (440.869).
INCY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for INCY turned positive on October 20, 2026. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in 23 of 35 cases over the following month. The odds of a continued upward trend are 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Indicator exited the oversold zone, 22 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INCY as a result. In 59 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in 207 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 61 cases where INCY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
INCY moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INCY crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
INCY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INCY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 27 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 28 (best 1 - 100 worst), indicating outstanding price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.823) is normal, around the industry mean (2.788). P/E Ratio (14.717) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (10.822) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (4.401) is also within normal values, averaging (440.869).
EXEL | INCY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 44 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 3 | 27 | |
SMR RATING 1..100 | 23 | 33 | |
PRICE GROWTH RATING 1..100 | 35 | 28 | |
P/E GROWTH RATING 1..100 | 20 | 72 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EXEL's Valuation (90) in the Biotechnology industry is in the same range as INCY (92). This means that EXEL’s stock grew similarly to INCY’s over the last 12 months.
EXEL's Profit vs Risk Rating (3) in the Biotechnology industry is in the same range as INCY (27). This means that EXEL’s stock grew similarly to INCY’s over the last 12 months.
EXEL's SMR Rating (23) in the Biotechnology industry is in the same range as INCY (33). This means that EXEL’s stock grew similarly to INCY’s over the last 12 months.
INCY's Price Growth Rating (28) in the Biotechnology industry is in the same range as EXEL (35). This means that INCY’s stock grew similarly to EXEL’s over the last 12 months.
EXEL's P/E Growth Rating (20) in the Biotechnology industry is somewhat better than the same rating for INCY (72). This means that EXEL’s stock grew somewhat faster than INCY’s over the last 12 months.
| EXEL | INCY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 60% | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 59% | 2 days ago 52% |
| Momentum ODDS (%) | 4 days ago 73% | 2 days ago 62% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 67% | 2 days ago 64% |
| Advances ODDS (%) | 3 days ago 68% | 10 days ago 63% |
| Declines ODDS (%) | 25 days ago 59% | 4 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 59% | 2 days ago 54% |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 53% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EXEL’s FA Score shows that 3 FA rating(s) are green while INCY’s FA Score has 3 green FA rating(s).
- EXEL’s FA Score: 3 green, 2 red.
- INCY’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EXEL’s TA Score shows that 4 TA indicator(s) are bullish while INCY’s TA Score has 4 bullish TA indicator(s).
- EXEL’s TA Score: 4 bullish, 4 bearish.
- INCY’s TA Score: 4 bullish, 6 bearish.
Price Growth
EXEL (@Biotechnology) experienced а +3.79% price change this week, while INCY (@Biotechnology) price change was -0.61% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -3.91%, and the average quarterly price growth was -15.16%.
Reported Earning Dates
EXEL is expected to report earnings on Feb 09, 2027.
INCY is expected to report earnings on Feb 09, 2027.
Industries' Descriptions
@Biotechnology (+7.94% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EXEL and
Correlation & Price change
A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with INCY. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then INCY could also see price increases.
| Ticker / NAME | Correlation To EXEL | 1D Price Change % | ||
|---|---|---|---|---|
| EXEL | 100% | -5.55% | ||
| INCY - EXEL | 51% Loosely correlated | -3.94% | ||
| MIRM - EXEL | 47% Loosely correlated | -3.54% | ||
| PTCT - EXEL | 43% Loosely correlated | -4.78% | ||
| RPRX - EXEL | 39% Loosely correlated | +0.01% | ||
| RIGL - EXEL | 37% Loosely correlated | -10.88% | ||
More | ||||